Beta Cat Pharmaceuticals, CerRx, DNAtrix, Essa Pharma, ProNAi, ProPep Surgical, Cancer Prevention and Research Institute of Texas cancer news
The institute awarded three-year grants totaling up to $63.2 million to six cancer companies based in or relocating to Texas. The institute also awarded $22.9 million for 11 research grants for academic projects and research training programs. Texas Gov. Rick Perry and state officials lifted a moratorium on the institute last year.
Among companies relocating to Texas, Essa Pharma will receive up to $12 million for a program to develop a blocker of N-terminal domain (NTD) of the androgen receptor for prostate cancer; and ProNAi Therapeutics will receive up to $14 million for Phase II testing of PNT2258, a cancer therapeutic targeting a DNA sequence upstream of B cell lymphoma 2 ( BCL-2; BCL2) promoters. Next quarter, ProNAi plans to start Phase II trials of PNT2258 in relapsed/refractory diffuse large B cell lymphoma (DLBCL) and front-line, high-risk DLBCL. Beta Cat will receive up to $15.9 million to develop inhibitors of a cancer cell target. ...